InvestorsHub Logo
Followers 140
Posts 11663
Boards Moderated 0
Alias Born 03/15/2011

Re: hutschi post# 318751

Friday, 11/17/2017 10:28:33 AM

Friday, November 17, 2017 10:28:33 AM

Post# of 346974
hutschi, thanks for all the articles. I wonder were the exosomes liquid biopsy of PPHM meets with the NEW all targets Avid platform.

I could be wrong but I think we are looking at TWO aspects of the SAME technology.

On the R&D side Exosomes require a party that will research the TEST Kit's. Ovarian will be the first and then OTHERS will have to come as it is said to work for ALL SOLID CANCERS.

On the CDMO side you have the applications of the Kits as a service to customers.

If PPHM splits R&D and AVID in two individual companies WE DO NOT WANT to be shareholders of AVID that pays licenses to the part with the R&D were we are NOT shareholders and CREAMS AWAY the buld of the profits we INVESTED IN.

That is ANOTHER DANGER on what is going on here that we need to watch.

Say that a TEST would cost 250$ (just naming an amount) and the Kit costs 25$ but is sold for 200$ to Avid and Avid's own cost is 25$ (sales, marketing, service) and would have the other 25$ as a profit then they will tell us this is a 100% profit situation.

But we invested in the 200-25$=175$ ALSO. We know that this platform is READY (or as good as). SO the COMPLETE PROFITS must come to us and not to a last minute before sell-out private or other party!

AIMO.

Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News